BioSpace News Archive

Magellan Health, Inc. announced financial results for the first quarter ended March 31, 2019, as summarized below:

KCI is a Leading Global Medical Technology Company Focused on Advanced Wound Care and Specialty Surgical Applications

Anixa Biosciences, Inc. announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference to be held May 22–23, 2019, at the Beverly Hilton Hotel in Beverly Hills, CA. Dr. Amit Kumar, Chairman, President and CEO of Anixa, will be presenting, as well as meeting with investors.

Spend base reduction of $2.5 billion since initiation of the restructuring plan in 2018; on-track to achieve $3.0 billion by the end of 2019

Abbott (NYSE: ABT) announced today that m-PIMA™ HIV-1/2 VL, the world’s first point-of-care viral load diagnostic test, has received the World Health Organization’s Prequalification approval (WHO PQ).

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced financial results for the first quarter 2019

CROP Infrastructure Corp. announced that its first Oklahoma farm’s tenant, Hempire Oklahoma has been issued Medical Cannabis Cultivation and processing licenses at its 1 acre location in Purcell, Oklahoma where the company will focus on high grade flower and extraction.

Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (‘KALY’) today announced the all new HempTantation, a hemp derived CBD infused sunscreen. KALY has a U.S. Patented cannabis extraction process.

Ormco Corporation, a leading provider of advanced orthodontic technology, today announced it will preview Spark Clear Aligner System, a new entry to the clear aligner category at the American Academy of Orthodontics (AAO) annual meeting in Los Angeles, May 3rd-7th, in advance of its upcoming U.S. launch

BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, (“BioLife” or the “Company”), today announced that the Company’s first quarter 2019 financial results will be released after market close on Thursday, May 9, 2019,